NewsBenzingaReported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Benzinga 2026.11.16 05:19 (GMT+0) Open on Benzinga Other news Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’ Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply Are Wall Street Analysts Bullish on Eversource Energy Stock? Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events Morning Bid: AI selloff resumes as Nvidia earnings loom Reported Sunday, Cocrystal Pharma Q3 EPS $(0.20) Misses $(0.18) Estimate, Sales $105.000K
Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’
Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events